Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone
Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.
How this was made

The 30-second read
Why it matters
The successful Phase 3 readout is a fresh, material development that could trigger a price rally ahead of the anticipated NDA submission.
Market read
First disclosure of pivotal trial success; likely to move PHVS and related rare‑disease biotech stocks.
What to watch
The company’s cash runway and upcoming NDA filing timelines may limit upside if financing is needed.
Background
Pharvaris (PHVS) provided a brief Q3 2026 update focusing on late‑stage development milestones for its HAE candidates.
Ticker impact
Pharvaris announced a successful pivotal Phase 3 readout for deucrictibant XR and disclosed NDA timelines, a new clinical‑trial milestone.
upward pressure as market anticipates regulatory approval and commercial launch
Phase 3 success is a material catalyst for biotech stocks; no prior public disclosure of this readout.
Market effects
Strengthens outlook for the hereditary angioedema therapeutic segment.
Potentially benefits European biotech investors tracking rare‑disease pipelines.
Adds to the pipeline momentum in the global rare‑disease biotech space.
Counterpoint
If regulatory hurdles delay, the stock could face disappointment despite trial success.
Key entities
- companyPharvaris
Biotech firm developing deucrictibant for hereditary angioedema.
